BlackRock Group’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-48,413
| Closed | -$144K | – | 3039 |
|
|
2016
Q3 | $144K | Hold |
48,413
| – | – | ﹤0.01% | 2733 |
|
|
2016
Q2 | $72K | Buy |
48,413
+36,263
| +298% | +$83K | ﹤0.01% | 2857 |
|
|
2016
Q1 | $44K | Buy |
12,150
+3,508
| +41% | +$21.7K | ﹤0.01% | 2948 |
|
|
2015
Q4 | $88K | Sell |
8,642
-732
| -8% | -$8.81K | ﹤0.01% | 2719 |
|
|
2015
Q3 | $128K | Buy |
9,374
+952
| +11% | +$16.9K | ﹤0.01% | 2649 |
|
|
2015
Q2 | $160K | Buy |
8,422
+1,475
| +21% | +$31.9K | ﹤0.01% | 2635 |
|
|
2015
Q1 | $182K | Buy |
6,947
+1,087
| +19% | +$27.7K | ﹤0.01% | 2525 |
|
|
2014
Q4 | $122K | Sell |
5,860
-23,715
| -80% | -$598K | ﹤0.01% | 2636 |
|
|
2014
Q3 | $987K | Buy |
29,575
+25,564
| +637% | +$793K | ﹤0.01% | 1793 |
|
|
2014
Q2 | $129K | Sell |
4,011
-95,815
| -96% | -$3.57M | ﹤0.01% | 2549 |
|
|
2014
Q1 | $4.61M | Buy |
99,826
+12,675
| +15% | +$743K | ﹤0.01% | 1136 |
|
|
2013
Q4 | $6.18M | Sell |
87,151
-12,847
| -13% | -$982K | ﹤0.01% | 1020 |
|
|
2013
Q3 | $8.57M | Buy |
99,998
+93,718
| +1,492% | +$7.94M | 0.01% | 954 |
|
|
2013
Q2 | $398K | Buy |
+6,280
| New | +$333K | ﹤0.01% | 2124 |
|
BlackRock Group's AEGR Position: Q4 2016 in Review
BlackRock Group sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 48,413 shares — an estimated $144K sold.
BlackRock Group first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $8.57M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- BlackRock Group reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- BlackRock Group sold 48,413 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $144K.
- BlackRock Group first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- BlackRock Group's Aegerion Pharmaceuticals position peaked at $8.57M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.